RANI Earnings
Rani Therapeutics Holdings Inc
$
0.500
- Overview
- Forecast
- Valuation
- Earnings
Earning Analysis
Welcome to our in-depth analysis of Rani Therapeutics Holdings Inc(RANI) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Rani Therapeutics Holdings Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
| FY2025Q2 | 2025-08-07 | After Hours | -0.19 | -0.18 | +5.26 | 170.00K | 0.00 | -100.00 | -0.94 | - |
| FY2025Q1 | 2025-05-13 | After Hours | -0.22 | -0.22 | - | 1,000K | 172.00K | -82.80 | +15.59 | +45.32 |
| FY2024Q4 | 2025-03-31 | After Hours | -0.24 | -0.27 | -12.50 | - | 1.03M | - | -2.38 | -3.97 |
| FY2024Q3 | 2024-11-14 | - | -0.22 | -0.24 | -9.09 | - | - | - | -4.86 | -17.00 |
| FY2024Q2 | 2024-08-06 | - | -0.29 | -0.26 | +10.34 | - | - | - | +2.46 | -2.79 |
| FY2024Q1 | 2024-05-06 | - | -0.23 | -0.29 | -26.09 | - | - | - | +5.73 | -11.75 |
| FY2023Q4 | 2024-03-20 | - | -0.31 | -0.27 | +12.90 | - | - | - | +0.56 | -10.42 |
| FY2023Q3 | 2023-11-08 | - | -0.47 | -0.36 | +23.40 | - | - | - | - | -0.25 |
| FY2023Q2 | 2023-08-11 | - | -0.40 | -0.37 | +7.50 | - | - | - | -0.71 | -5.20 |
| - | 2023-05-10 | - | -0.47 | -0.33 | +29.79 | - | - | - | -1.60 | -6.64 |
RANI Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Rani Therapeutics Holdings Inc reported performance for FY2025Q2, announced on 2025-08-07. The company achieved an EPS of -0.18, compared to analyst estimates of -0.19 by 5.26% . Revenue for the quarter reached 0.00 compared to expectations of 170.00K by -100.00% .
The stock price reacted with a -0.94% one-day change and a % five-day change following the earnings release. These movements reflect market reaction in Rani Therapeutics Holdings Inc growth trajectory and strategic initiatives.
RANI Earnings Forecast
Looking ahead, Rani Therapeutics Holdings Inc(RANI) remains a focal point for investors seeking growth opportunities. Analyst forecasts for project quarter revenue of and an EPS of .
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for have been Go Down by -18.43%, while EPS estimates have been No Change by %. For the upcoming , revenue estimates have been adjusted No Change by % . These revisions correlate with a % change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Rani Therapeutics Holdings Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between RANI's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Stock Price
Go Down
-18.43%
In Past 3 Month
1Y
3Y
5Y
Fiscal Period
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-:0
--
EPS Estimate-:0
—
Stock Price0.50
RANI Revenue and EPS Performance: A Historical Perspective
Rani Therapeutics Holdings Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q2 (2025-08-07,After Hours):
EPS: -0.18 (Actual) vs.-0.19 (Estimate) (5.26%)
Revenue: 0.00 (Actual) vs. 170.00K (Estimate) (-100.00%)
Price Reaction: -0.94%(1-Day), %(5-Day)
FY2025Q1 (2025-05-13,After Hours):
EPS: -0.22 (Actual) vs.-0.22 (Estimate) (0.00%)
Revenue: 172.00K (Actual) vs. 1,000K (Estimate) (-82.80%)
Price Reaction: 15.59%(1-Day), 45.32%(5-Day)
FY2024Q4 (2025-03-31,After Hours):
EPS: -0.27 (Actual) vs.-0.24 (Estimate) (-12.50%)
Revenue: 1.03M (Actual) vs. 0.00 (Estimate) (%)
Price Reaction: -2.38%(1-Day), -3.97%(5-Day)
Earnings Reaction
The chart below shows how RANI performed 10 days before and after its earnings report, based on data from the past quarters. Typically, RANI sees a +16.41% change in stock price 10 days leading up to the earnings, and a -1.39% change 10 days following the report. On the earnings day itself, the stock moves by -3.02%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in JUN/2025, the stock changed -0.94% on the day following the earnings release and then changed by -6.19% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Rani Therapeutics Holdings Inc (RANI) Q4 2024 Earnings Call Summary
Negative
2025-04-01
The earnings call reveals significant challenges: a decrease in cash reserves, operational cost constraints, and an impairment loss. The lack of a share repurchase program and competitive pressures also weigh negatively. While there is interest in the RaniPill and a focus on RT-114, the lack of clear guidance on costs and capital constraints suggest potential struggles. The overall sentiment from the Q&A is cautious, with concerns about financial health and competitive positioning. These factors suggest a negative stock price movement in the short term.
Rani Therapeutics Holdings Inc (RANI) Q4 2024 Earnings Call Summary
Negative
2025-03-31
The earnings call summary indicates several concerns: a significant net loss, regulatory and competitive pressures, supply chain challenges, and decreased cash reserves. The Q&A section revealed unclear management responses, especially regarding cost management and prioritization, which could worry investors. Despite some cost reductions and a slight revenue increase, the lack of a share repurchase program and impairment losses further contribute to a negative outlook. These factors suggest a negative stock price reaction over the next two weeks.
Rani Therapeutics Holdings Inc (RANI) Q4 2024 Earnings Call Summary
Negative
2025-03-31
The earnings call reveals significant challenges, including financial losses, regulatory risks, competitive pressures, and supply chain issues. Despite reduced expenses and some revenue growth, the absence of a shareholder return plan and unclear management responses in the Q&A heighten concerns. The lack of new partnerships or positive financial guidance, coupled with impairment losses and a decreased cash position, further contribute to a negative sentiment. Without market cap data, the prediction leans towards a negative reaction, potentially between -2% to -8%.
People Also Watch
FAQ
What were the key highlights of RANI’s latest earnings report for FY2025Q2?
RANI reported its FY2025Q2 earnings on 2025-08-07, showcasing a revenue of 0.00 against an estimate of 170.00K, resulting in a -100% surprise. The EPS was -0.18, surpassing the expected -0.19 by 5.26% . The stock experienced a -0.94% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.
How did RANI’s stock price react after the FY2025Q2 earnings release?
What are the revenue and EPS estimates for RANI for undefined?
How does RANI’s stock price correlate with earnings forecast revisions?
What should investors expect from RANI’s next earnings report?